Co-investigator o principal investigator (*) di diversi “trials” mono e multicentrici nazionali e internazionali, tra cui:
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism - The COLUMBUS Investigators - N Engl J Med 1997;337; 657-62.
Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity -
A Phase II Evaluation - The REMBRANDT Investigators – Circulation 2000;102:2726-2731.
Risk factors for chronic thromboembolic pulmonary hypertension and the "Pavia Pulmonary Endarterectomy Program" - in Multidisciplinary respiratory medicine 3(6):440-444 - December 2008.
The Effect of Prothrombotic Blood Abnormalities on Risk of Deep Vein Thrombosis in Users of Hormone Replacement Therapy: A Prospective Case-Control Study - Clin Appl Thromb Hemost 17(6):E106-13 - November 2011·
Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs - CALISTO Study Group - N Engl J Med 2010; 363: 1222-32.
Oral Rivaroxaban for Symptomatic Venous Thromboembolism - The EINSTEIN Investigators - N Engl J Med 2010; 363: 2499-510.
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis - The EQUINOX Investigators - J Thromb Haemost 2011; 9: 92–9.
Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism - The EINSTEIN–PE Investigators - N Engl J Med 2012; 366: 1287-97.
(*) Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial - The CASSIOPEA Investigators - Lancet 2012; 379: 123–29.
Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism - Journal of Thrombosis and Haemostasis July 2017 15(7):1436-1442·